title: Anti-aminoacyl-tRNA synthetase antibodies in clinical course prediction of interstitial lung disease complicated with idiopathic inflammatory myopathies.
abstract: In the treatment of polymyositis and dermatomyositis (PM/DM), the complication of interstitial lung disease (ILD) is an important prognostic factor. It has been reported that autoantibodies against aminoacyl-tRNA synthetases (ARS) are strongly associated with ILD. The aim of this study is to examine the correlation between anti-ARS and the clinical course of ILD. We investigated 41 cases of PM/DM with ILD. The response of ILD to corticosteroids (CS) was determined according to the change in respiratory symptoms, image findings, and pulmonary function between, before and 2 months after the treatment. Anti-ARS (anti-Jo-1, PL-7, PL-12, EJ, OJ and KS) antibodies were screened with the RNA immunoprecipitation assay. In the stratification into ILD-preceding, simultaneous and myopathy-preceding types, anti-ARS antibodies were significantly frequent in the ILD-preceding type (p < 0.05). In the stratification into anti-ARS-positive and negative groups, the response of ILD to CS was significantly better in the positive group (p < 0.05). However, recurrence of ILD was significantly more frequent in the positive group (p < 0.01), and 2 year prognoses of pulmonary function (%VC and %DLCO) were not different between the two groups. In conclusion, screening of anti-ARS may be useful to predict late-onset myopathy in ILD-preceding patients and to predict the clinical course of ILD in PM/DM patients.
authors.affiliation: Kyoto University, Graduate School of Medicine, Department of Rheumatology and Clinical Immunology, Japan. yoshifuj@kuhp.kyoto-u.ac.jp
authors.forename: Hajime
authors.initials: H
authors.lastname: Yoshifuji
authors.forename: Takao
authors.initials: T
authors.lastname: Fujii
authors.forename: Shio
authors.initials: S
authors.lastname: Kobayashi
authors.forename: Yoshitaka
authors.initials: Y
authors.lastname: Imura
authors.forename: Yoshimasa
authors.initials: Y
authors.lastname: Fujita
authors.forename: Daisuke
authors.initials: D
authors.lastname: Kawabata
authors.forename: Takashi
authors.initials: T
authors.lastname: Usui
authors.forename: Masao
authors.initials: M
authors.lastname: Tanaka
authors.forename: Sonoko
authors.initials: S
authors.lastname: Nagai
authors.forename: Hisanori
authors.initials: H
authors.lastname: Umehara
authors.forename: Tsuneyo
authors.initials: T
authors.lastname: Mimori
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000604:Amino Acyl-tRNA Synthetases / Q000276:immunology*; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage; D001323:Autoantibodies / Q000097:blood*; D005260:Female; D006801:Humans; D047468:Immunoprecipitation; D017563:Lung Diseases, Interstitial / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology*; D008297:Male; D008875:Middle Aged; D009220:Myositis / Q000150:complications* / Q000175:diagnosis / Q000503:physiopathology; D011239:Prednisolone / Q000008:administration & dosage
chemical_list: D000893:Anti-Inflammatory Agents; D001323:Autoantibodies; D011239:Prednisolone; D000604:Amino Acyl-tRNA Synthetases